Stoke Therapeutics, Inc.

STOKSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1623526

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	$8.8M	$12.4M	$12.4M	—	—
Research and Development Expense	$82.2M	$77.8M	$54.2M	$32.2M	$23.8M
Operating Expenses	$123.6M	$116.8M	$86.1M	$53.0M	$6.3M
Operating Income (Loss)	-$114.8M	-$104.4M	-$86.1M	-$53.0M	-$6.3M
Interest Expense	$49.0K	—	—	—	—
Nonoperating Income (Expense)	$10.1M	$3.3M	$260.0K	$801.0K	$3.4M
Net Income (Loss) Attributable to Parent	-$104.7M	-$101.1M	-$85.8M	-$52.2M	-$5.7M
Earnings Per Share, Basic

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$228.3M	$256.1M	$238.9M	$297.9M	$228.8M
Assets, Current	$215.3M	$244.1M	$229.2M	$293.9M	$226.0M
Cash and Cash Equivalents, at Carrying Value	$191.4M	$113.6M	$144.9M	$287.3M	$222.5M
Liabilities	$68.8M	$71.2M	$21.1M	$11.8M	$4.3M
Liabilities, Current	$30.8M	$31.4M	$17.1M	$11.4M	$4.1M
Accounts Payable, Current	$1.7M	$766.0K	$2.4M	$1.5M	$751.0K
Stockholders' Equity Attributable to Parent	$184.8M	$217.8M	$286.1M	$224.4M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$81.1M	-$31.9M	-$66.9M	-$42.2M	-$31.1M
Net Cash Provided by (Used in) Investing Activities	$105.9M	-$45.9M	-$76.4M	-$1.1M	-$1.6M
Net Cash Provided by (Used in) Financing Activities	$53.0M	$46.4M	$1.3M	$108.1M	$149.8M
Payments to Acquire Property, Plant, and Equipment	$1.6M	$4.0M	$1.2M	$1.1M	$1.6M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)